Spero Therapeutics Inc
SPRO
Get informed when a big investor buys or sells
+ FollowMarket Cap$69.48M
Close$
$5.29
333.9% upside
Current Fair Value
333.9% upsideUndervalued by 333.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $69.48 Million |
|---|---|
| Enterprise Value | $20.91 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.15 |
| Beta | 1.48 |
| Outstanding Shares | 57,968,608 |
Return
| Return on Equity | 16.70% |
|---|---|
| Return on Assets | 13.99% |
| Return on Invested Capital | 10.74% |
Valuation & Multiples
| P/E Ratio | 8.57 |
|---|---|
| PEG | 1.86 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.46 |
| Enterprise Value to EBIT | 4.39 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.6977▲ 169.77% |
|---|---|
| Total Calls | 64,500▲ Infinity% |
| Total Puts | 109,500▼ 1.97% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 36.04%▼ 1.66% |
|---|---|
| Total Invested | $48.30M▼ 1.86% |
| Investors Holding | 55▼ 3.00% |
ESG Score
No data
About Spero Therapeutics Inc
89 employees
CEO: Ankit Mahadevia Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.